Mayo Clinic

Anumana is a technology company that specializes in developing artificial intelligence algorithms to analyze electrocardiogram (ECG) data, facilitating early diagnosis of cardiovascular conditions. By leveraging advanced machine learning techniques, Anumana's platform enhances cardiac care, providing healthcare professionals with tools to identify potential heart issues efficiently. The company's focus extends beyond diagnostics to improve patient outcomes across the entire continuum of cardiovascular care, including perioperative and acute settings. Through its innovative approach, Anumana aims to refine screening processes, enabling clinicians to detect heart diseases earlier and intervene more effectively, ultimately contributing to improved healthcare delivery and management of cardiovascular health.

Myosin Therapeutics is a privately-held biopharmaceutical company dedicated to developing innovative medications for central nervous system (CNS) disorders and other significant unmet medical needs. The company focuses on creating novel drugs that target cellular motor proteins, which are essential molecular machines that convert energy into mechanical work within cells. This unique approach enables the potential treatment of various disease states, including cancer. By harnessing the capabilities of these motor proteins, Myosin Therapeutics aims to advance therapeutic options and improve patient outcomes in challenging medical areas.

Delfina is a company that specializes in developing a personalized prenatal care system aimed at ensuring the safety of mothers and infants during pregnancy. By leveraging data and machine learning, Delfina's platform creates individualized pregnancy care plans that assess patient risk through various metrics. This approach not only enhances interventional workflows but also improves provider efficiency, facilitating early intervention in prenatal care. Delfina's commitment to data-driven insights is paving the way for clinical innovation, ultimately striving to deliver equitable and cost-effective healthcare solutions for expectant families.

Jupiter Bioventures is a venture builder firm dedicated to supporting early-stage therapeutic projects. The company aims to de-risk these initiatives by carefully evaluating opportunities against specific investment criteria. By providing small amounts of seed capital, Jupiter Bioventures enables founders to cultivate their projects and advance their development. Through its focused approach, the firm plays a crucial role in fostering innovation in the therapeutic sector.

Aignostics GmbH, founded in 2018 and based in Berlin, Germany, specializes in AI-powered diagnostics and pathology software solutions aimed at enhancing pharmaceutical research and clinical diagnostics. The company focuses on precision diagnostics in pathology, employing its patented technology to create explainable AI systems that address the limitations of traditional AI models. By generating precise heatmaps and image overlays, Aignostics' platform enables pathologists to quickly verify AI-generated diagnostic results. This capability is essential for ensuring accuracy in diagnoses, particularly for complex diseases such as cancer. The company's innovative approach supports the discovery and validation of biomarkers, facilitating improved diagnosis and treatment strategies in precision medicine.

Endogenex is a medical technology company founded in 2017 that focuses on developing an innovative endoscopic procedure to assist patients with type 2 diabetes in managing their blood glucose levels. The company has created a unique therapy that employs pulsed electric fields to promote the regeneration of the duodenal mucosa, which contributes to enhanced glycemic control. By providing this novel treatment option, Endogenex aims to improve the quality of life for individuals living with type 2 diabetes.

Qlaris Bio, Inc. is a clinical-stage biotechnology company based in Wellesley, Massachusetts, focused on developing innovative therapies for serious ophthalmic diseases. Founded in 2017, the company is working on QLS-101, a therapy aimed at reducing intraocular pressure, a critical factor in conditions such as glaucoma. Qlaris Bio explores novel mechanisms to address episcleral venous pressure, which significantly contributes to intraocular pressure, thereby aiming to mitigate the risk of blindness associated with both Primary Open Angle Glaucoma and Normal Tension Glaucoma. The company also targets high unmet medical needs in pediatric rare diseases related to intraocular pressure disturbances, where effective treatment options are currently limited.

UpDoc is a technology-enabled services firm that offers the world's first unique conversational AI platform for autonomous prescription management.

Abridge Inc. is a healthcare technology company founded in September 1999, focused on enhancing communication in medical settings through innovative tools. The company utilizes generative AI to automate the transcription and summarization of patient-clinician conversations, converting these interactions into structured clinical notes in real-time. This platform integrates seamlessly with Electronic Health Record (EHR) systems, significantly reducing the need for manual note-taking. By generating clear and understandable summaries, Abridge improves patient comprehension of medical discussions and ensures that relevant documentation is accurately recorded in patient files. Additionally, the company emphasizes data security and patient privacy, adhering to healthcare regulations while providing a customizable interface that caters to individual patient needs.

Nucleus RadioPharma is a company focused on enhancing access to innovative radiopharmaceuticals for cancer patients. It is dedicated to developing technologies that modernize the clinical development, manufacturing, and supply chain processes associated with these therapies. By specializing in novel treatments and technologies, Nucleus RadioPharma aims to improve the diagnosis and treatment of various cancers, ensuring that healthcare professionals can effectively utilize these advanced medical solutions.

EBAMed SA is a Swiss startup based in Geneva, established in 2018, that focuses on developing innovative medical technology for treating heart arrhythmias. The company is working on an ultrasound-based device designed to monitor heart motion and facilitate non-invasive ablation therapy using proton beams. This technology aims to provide a safe and effective alternative for patients by allowing real-time synchronization of proton therapy with heart movement. By integrating both hardware and software components, EBAMed's device enhances treatment capabilities for existing proton therapy centers, enabling them to offer advanced, non-invasive treatment options for cardiac patients in an outpatient setting.

AccurKardia is a diagnostics software company specializing in ECG-led technology aimed at enhancing patient outcomes and saving lives worldwide. The company's flagship product, AccurECG™, is a cloud-based, FDA-cleared software that enables fully automated, near real-time interpretation of ECG data. AccurKardia has developed additional solutions, including AK+ Guard™, an AI-driven tool for early detection of hyperkalemia using Lead I ECG data, which has received FDA Breakthrough Device Designation. The company also created the AK-AVS™ model for aortic stenosis detection, which similarly attained Breakthrough Device Designation. AccurKardia's innovative platform combines proprietary artificial intelligence with traditional techniques to deliver clinical-grade ECG analytics, assisting cardiac monitoring companies in analyzing ECGs from various devices. The company has participated in notable accelerator programs, including the 2024 Cohort of MedTech Innovator and the American Heart Association’s Heart and Brain Health Accelerator track, further establishing its commitment to advancing cardiovascular health technology.

Medivis is a developer of advanced medical imaging technology that utilizes augmented reality and artificial intelligence to enhance surgical operations. The company's innovative platform enables physicians to overlay holographic images directly onto patients during procedures, facilitating precise decision-making in the operating room. By integrating these technologies, Medivis aims to improve surgical outcomes and streamline the workflow for healthcare professionals, ultimately advancing the field of surgical navigation.

Lucem Health is a company focused on developing a remote diagnostics platform that integrates remote patient telemetry and biosensing devices with artificial intelligence algorithms. The platform is designed to enhance data ingestion, orchestration, and connectivity, which allows clinicians to deliver more effective continuous care. It supports the development and deployment of clinical AI models that facilitate point-of-care solutions, enabling healthcare providers to gain valuable insights directly from clinical data. By streamlining the execution of AI models and integrating these insights into clinical workflows, Lucem Health empowers both clinicians and consumers to improve health management and enhance overall well-being.

Mediwhale is a health diagnostics company that focuses on leveraging artificial intelligence to enhance the prevention of cardiovascular and kidney diseases. It operates a unique AI screening platform that assesses metabolic risks and diagnoses eye diseases through non-invasive retinal scans. The platform comprises several components, including RetiCVD for cardiovascular disease risk assessment, which utilizes coronary artery calcium scores to predict risks based on established guidelines. RetiCKD offers a chronic kidney disease risk assessment with improved predictive capabilities compared to traditional methods. Additionally, RetiEYE identifies common age-related eye diseases like diabetic retinopathy and glaucoma at their referable stages. Mediwhale's retinal-based systemic biomarkers have been clinically validated and are recognized in the medical community, supported by publications in reputable journals. Through its innovative approach, Mediwhale aims to establish a sustainable healthcare model that emphasizes early detection and intervention.

R-Zero is a company specializing in smart building technology and biosafety solutions aimed at enhancing indoor environments. It offers a suite of products designed to improve workforce productivity and optimize real estate utilization while promoting health and safety. R-Zero's portfolio includes advanced indoor air quality and comfort monitoring systems, high-efficiency HVAC filtration, occupancy-based building controls, and space utilization sensors. Additionally, the company provides mobile UV-C units that effectively disinfect large spaces, aiding in the reduction of infectious disease transmission. With a focus on operational efficiency, R-Zero's connected platform delivers real-time insights that empower building owners and operators to adapt their properties for future demands while ensuring a safe and productive environment for tenants.

Acorai is developing a non-invasive heart failure monitoring platform centered on direct intracardiac pressure monitoring (ICPM). The company utilizes a patented combination of sensor technologies and machine learning to provide accurate and cost-efficient heart failure care. This innovative approach allows for non-invasive monitoring of cardiac and pulmonary pressure, which is crucial for improving outcomes in heart failure patients. By analyzing pressure dynamics through acoustic, vibratory, and waveform data, the device enables healthcare professionals to proactively adjust medications, potentially reducing re-hospitalization and mortality rates associated with heart failure. Clinically validated and designated as an FDA Breakthrough Device, Acorai's product is expected to enter the market in 2025.

Nucleus RadioPharma is a company focused on enhancing access to innovative radiopharmaceuticals for cancer patients. It is dedicated to developing technologies that modernize the clinical development, manufacturing, and supply chain processes associated with these therapies. By specializing in novel treatments and technologies, Nucleus RadioPharma aims to improve the diagnosis and treatment of various cancers, ensuring that healthcare professionals can effectively utilize these advanced medical solutions.

Senda Biosciences, founded in 2017 by David Kolesky, Ignacio Martinez, and John Casey in Cambridge, Massachusetts, focuses on developing therapeutic applications for innovative treatments of human diseases. The company specializes in studying the molecular relationships between bacterial, botanical, and human cells to understand how these interactions influence health and disease. By gaining insights into these interspecies connections, Senda Biosciences aims to create novel categories of medicines and delivery methods, providing medical professionals with new tools to combat various illnesses.

Diagnostic Robotics Ltd is an Israeli company, founded in 2017 and headquartered in Tel Aviv, that specializes in developing artificial intelligence solutions for the healthcare sector. The company offers a signal-agnostic AI system designed to assist healthcare insurers, providers, and patients by creating predictive analytics models. These models aim to address significant clinical and financial challenges faced by the healthcare industry, ultimately optimizing clinical program performance and improving return on investment. By enabling healthcare systems to deliver more effective care at reduced costs, Diagnostic Robotics facilitates informed decision-making and proactive interventions in patient care.

Karkinos Healthcare is a technology-driven platform that focuses on oncology, aiming to provide accessible cancer care and early diagnosis of common cancers. The company develops comprehensive healthcare solutions that bring cancer services closer to patients, ensuring that access and affordability do not hinder individuals from receiving necessary care. By emphasizing early detection and diagnosis, Karkinos Healthcare strives to improve patient outcomes and make cancer care more inclusive for everyone.

Vyriad, Inc. is a clinical-stage biotechnology company focused on developing targeted cancer therapies through the use of engineered viruses. These therapies, which include oncolytic immunovirotherapy products derived from oncolytic vesicular stomatitis virus and oncolytic measles virus platforms, are designed to selectively target and destroy cancer cells while sparing normal tissues. Vyriad's innovative approach aims to not only treat cancer but also to stimulate immune responses that can prevent recurrence. Additionally, the company is engaged in creating diagnostic and theranostic tests to accurately predict patient responses to its immunovirotherapy treatments. Vyriad's foundational research is supported by collaboration with prominent institutions such as the Mayo Clinic and the University of Miami. Established in 2012, Vyriad is headquartered in Rochester, Minnesota.

Theator Inc. is a surgical intelligence platform based in San Mateo, California, focused on enhancing surgeon performance through the use of artificial intelligence and computer vision. Founded in 2018, the company offers a personalized video platform called Minutes, which analyzes and houses video data from surgical procedures. This platform includes content management software and a visual operative report featuring analytics, allowing surgeons to review past surgeries for educational purposes. By extracting and annotating critical moments from real-world procedures, Theator enables surgeons to gain valuable insights into their performances and those of their peers, thereby promoting continuous improvement and expertise within the operating room. Theator collaborates with innovative surgeons and hospitals to foster a more transparent surgical environment.

Tympany Medical focuses on advancing minimally invasive ear surgeries through innovative technology. The company has developed a specialized ear surgery device that provides a sterile endoscopic solution for complex procedures in otolaryngology. This device addresses key challenges related to the usability and flexibility of traditional endoscopes, allowing surgeons to benefit from enhanced visualization while preserving their two-handed operating techniques. By reducing the necessity for mastoidectomies, Tympany Medical aims to improve surgical outcomes and streamline the process of ear surgeries, ultimately enhancing patient care in the field of ENT.

SimBioSys is focused on advancing cancer care through its innovative Computational Microscope, which combines cutting-edge simulation techniques with extensive experimental datasets. This technology allows researchers to examine the cancer microenvironment, gaining insights into tumor behavior, cell phenotypes, and interactions with surrounding tissues. By transforming comprehensive diagnostic datasets into personalized virtual tumors, SimBioSys enhances decision-making for healthcare providers and improves patient experiences in cancer treatment. Ultimately, the platform aims to facilitate a deeper understanding of cancer dynamics, enabling more effective and tailored therapeutic approaches.

Laplace Interventional is a medical device company focused on developing transcatheter tricuspid valve technology aimed at treating tricuspid regurgitation. The company's innovative prosthetic valve is delivered through a minimally invasive procedure, eliminating the need for open-heart surgery. This approach not only enhances patients' life expectancy but also significantly improves their quality of life by reducing the risk of future complications. Through its advancements in cardiac care, Laplace Interventional is dedicated to providing effective solutions for patients worldwide.

R-Zero is a company specializing in smart building technology and biosafety solutions aimed at enhancing indoor environments. It offers a suite of products designed to improve workforce productivity and optimize real estate utilization while promoting health and safety. R-Zero's portfolio includes advanced indoor air quality and comfort monitoring systems, high-efficiency HVAC filtration, occupancy-based building controls, and space utilization sensors. Additionally, the company provides mobile UV-C units that effectively disinfect large spaces, aiding in the reduction of infectious disease transmission. With a focus on operational efficiency, R-Zero's connected platform delivers real-time insights that empower building owners and operators to adapt their properties for future demands while ensuring a safe and productive environment for tenants.

Senda Biosciences, founded in 2017 by David Kolesky, Ignacio Martinez, and John Casey in Cambridge, Massachusetts, focuses on developing therapeutic applications for innovative treatments of human diseases. The company specializes in studying the molecular relationships between bacterial, botanical, and human cells to understand how these interactions influence health and disease. By gaining insights into these interspecies connections, Senda Biosciences aims to create novel categories of medicines and delivery methods, providing medical professionals with new tools to combat various illnesses.

Helix is a prominent population genomics company that focuses on the convergence of clinical care, research, and genomics. Its comprehensive platform assists health systems, life sciences companies, and payers in advancing genomic research and integrating genomic data into clinical practice. Helix operates one of the world's largest CLIA/CAP-certified next-generation sequencing labs and utilizes its proprietary Exome+ assay to support various aspects of population genomics, including participant recruitment, disease screening, result reporting, and both basic and translational research.

Anumana is a technology company that specializes in developing artificial intelligence algorithms to analyze electrocardiogram (ECG) data, facilitating early diagnosis of cardiovascular conditions. By leveraging advanced machine learning techniques, Anumana's platform enhances cardiac care, providing healthcare professionals with tools to identify potential heart issues efficiently. The company's focus extends beyond diagnostics to improve patient outcomes across the entire continuum of cardiovascular care, including perioperative and acute settings. Through its innovative approach, Anumana aims to refine screening processes, enabling clinicians to detect heart diseases earlier and intervene more effectively, ultimately contributing to improved healthcare delivery and management of cardiovascular health.

Anumana is a technology company that specializes in developing artificial intelligence algorithms to analyze electrocardiogram (ECG) data, facilitating early diagnosis of cardiovascular conditions. By leveraging advanced machine learning techniques, Anumana's platform enhances cardiac care, providing healthcare professionals with tools to identify potential heart issues efficiently. The company's focus extends beyond diagnostics to improve patient outcomes across the entire continuum of cardiovascular care, including perioperative and acute settings. Through its innovative approach, Anumana aims to refine screening processes, enabling clinicians to detect heart diseases earlier and intervene more effectively, ultimately contributing to improved healthcare delivery and management of cardiovascular health.

Diagnostic Robotics Ltd is an Israeli company, founded in 2017 and headquartered in Tel Aviv, that specializes in developing artificial intelligence solutions for the healthcare sector. The company offers a signal-agnostic AI system designed to assist healthcare insurers, providers, and patients by creating predictive analytics models. These models aim to address significant clinical and financial challenges faced by the healthcare industry, ultimately optimizing clinical program performance and improving return on investment. By enabling healthcare systems to deliver more effective care at reduced costs, Diagnostic Robotics facilitates informed decision-making and proactive interventions in patient care.

nference, Inc. is a biotechnology company that specializes in an AI-based software platform designed to synthesize and analyze biomedical information. Founded in 2013 and headquartered in Cambridge, Massachusetts, with additional offices in Bengaluru, Toronto, and Rochester, nference focuses on transforming unstructured and structured data from biomedical literature, electronic medical records, and real-world datasets. The company's technology utilizes neural networks to automate the extraction of insights from diverse datasets, facilitating advancements in drug discovery, life cycle management, and precision medicine. By providing comprehensive biological and clinical insights, nference aims to support pharmaceutical, biotechnology, and healthcare enterprises in overcoming challenges in drug development and clinical research, ultimately enabling the discovery of personalized diagnostics and treatments for patients.

Progentec Diagnostics, Inc. is a company focused on developing innovative diagnostic tests for managing systemic lupus erythematosus (SLE). Established in 2015 and headquartered in Oklahoma City, Oklahoma, the company has created the aiSLE DX platform, which offers tools like a flare prediction score to measure disease activity in SLE patients and an early diagnostic test for lupus. Progentec integrates advanced technology and collaborates with research institutions globally, aiming to address significant unmet needs in diagnostic interventions. The company's mission centers on improving disease management and reducing disease incidence through enhanced screening and early detection.

nference, Inc. is a biotechnology company that specializes in an AI-based software platform designed to synthesize and analyze biomedical information. Founded in 2013 and headquartered in Cambridge, Massachusetts, with additional offices in Bengaluru, Toronto, and Rochester, nference focuses on transforming unstructured and structured data from biomedical literature, electronic medical records, and real-world datasets. The company's technology utilizes neural networks to automate the extraction of insights from diverse datasets, facilitating advancements in drug discovery, life cycle management, and precision medicine. By providing comprehensive biological and clinical insights, nference aims to support pharmaceutical, biotechnology, and healthcare enterprises in overcoming challenges in drug development and clinical research, ultimately enabling the discovery of personalized diagnostics and treatments for patients.

Novome Biotechnologies, Inc. is a biotechnology company that focuses on engineering bacteria from the human gut to develop innovative treatments for chronic diseases. Its proprietary platform, which allows for the controlled colonization of the gut with genetically engineered microbial medicines (GEMMs), is designed to provide sustained therapeutic effects. Novome's lead preclinical program targets hyperoxaluria by developing a therapeutic strain of bacteria that degrades oxalate, thereby preventing kidney stone formation. The company aims to leverage its synthetic biology tools to expand its applications into additional health conditions, enhancing its ability to deliver precise therapeutic activities through engineered gut microbiota. Founded in 2015, Novome is headquartered in South San Francisco, California.

HuidaGene Therapeutics Co., Ltd. is a biotechnology company based in Shanghai, China, founded in 2018. The company specializes in the research and development of gene therapies for single-gene disorders and is expanding its focus to neurodegenerative diseases and vision disorders. HuidaGene employs its proprietary CRISPR-based and AI-driven HG-PRECISE platform to create potentially curative therapies. Among its clinical programs, HuidaGene is advancing HG004 for RPE65-associated retinal disease, HG202 for neovascular age-related macular degeneration, HG204 for MECP2 duplication syndrome, and HG302 for Duchenne muscular dystrophy. Several of these therapies have received orphan drug designations and rare pediatric disease designations from regulatory authorities. In addition to its clinical initiatives, the company is exploring preclinical programs, including HG303 for amyotrophic lateral sclerosis and a CRISPR RNA-editing therapy for Alzheimer’s disease.

NewCompliance is a healthcare technology company focused on enhancing the quality and safety of patient care through its innovative platform. The company collaborates with industry partners such as Stryker, Medtronic, Skytron, and Philips to deliver interoperable IT solutions. Its flagship product, the ACTIQ platform, offers predictive dashboarding and analytics, allowing medical personnel to access real-time feedback and management information. This technology is designed to support caregivers in departments such as surgery, emergency care, and intensive care, ultimately aiming to reduce costs, improve hospital safety, and enhance patient satisfaction throughout the surgical patient journey. By prioritizing efficiency and effectiveness, NewCompliance positions itself as a leader in the healthcare technology sector.

FundamentalVR have been working with leading pharmaceutical companies to combine virtual and mixed reality with haptic feedback using their ‘FeelRealVR’ platform to create simulated surgical procedures to help educate and train healthcare professionals. The company works at the nexus of haptics, machine learning, and immersive technologies (XR). FundamentalVR was established in 2012 by Chris Scattergood in London, England.

AtriAN Medical is an Irish medical device company based in Galway, specializing in innovative treatments for atrial fibrillation. The company has commercialized technology developed at the Mayo Clinic, focusing on a unique approach that utilizes micro Pulsed Electric Fields (mPEF) to selectively ablate hyperactive tissues while preserving surrounding myocardial tissue. AtriAN's device employs a catheter to deliver short pulses of electrical energy to the clusters of neuronal cells responsible for the condition. This method allows for effective treatment without causing damage to the heart muscle, offering physicians a new option in managing atrial fibrillation and improving patient outcomes.

Qlaris Bio, Inc. is a clinical-stage biotechnology company based in Wellesley, Massachusetts, focused on developing innovative therapies for serious ophthalmic diseases. Founded in 2017, the company is working on QLS-101, a therapy aimed at reducing intraocular pressure, a critical factor in conditions such as glaucoma. Qlaris Bio explores novel mechanisms to address episcleral venous pressure, which significantly contributes to intraocular pressure, thereby aiming to mitigate the risk of blindness associated with both Primary Open Angle Glaucoma and Normal Tension Glaucoma. The company also targets high unmet medical needs in pediatric rare diseases related to intraocular pressure disturbances, where effective treatment options are currently limited.

GYANT is a digital front door solution for health systems that utilizes artificial intelligence to enhance patient navigation to appropriate care settings and in-network resources. By implementing digital patient journeys, GYANT enables health systems to effectively capture new patients and efficiently serve existing ones. The platform employs natural language processing to understand patients' needs, guiding them through their healthcare encounters. This not only improves patient engagement but also enhances care utilization, leading to better access to healthcare services. Additionally, GYANT contributes to process automation within health systems, ultimately resulting in lower costs and time savings for healthcare providers.

Pendulum Therapeutics Inc. is a microbiome-focused company based in San Francisco that specializes in developing medical probiotics and prebiotics aimed at managing chronic illnesses, particularly type 2 diabetes. The company's flagship product, Pendulum Glucose Control, was introduced in 2020 and has demonstrated effectiveness in lowering blood sugar spikes and reducing A1C levels, as evidenced by published clinical trials. Pendulum utilizes evidence-based microbiome science and DNA sequencing to create targeted interventions, allowing clinicians to identify specific microbiome markers for disease treatment. Founded in 2013, Pendulum holds 13 patents and has 42 pending, with significant backing from prominent investors. The company sells its products online, focusing on improving healthcare through innovative microbiome therapies.

Giblib is a California-based company founded in 2015, headquartered in Los Angeles. It operates an online video community platform that serves as a resource for medical education, specifically targeting surgical procedures across various specialties. The platform allows surgeons to share curated medical lectures and surgical videos, providing valuable insights into surgical techniques and practices. By indexing every surgical procedure, Giblib enables medical students and practitioners to access high-quality educational content from experienced professionals, enhancing their understanding of medicine and surgery.

StemoniX Inc. is a biotechnology company specializing in stem cell technologies to enhance drug discovery and personalized medicine. Founded in 2014 and headquartered in Minneapolis, Minnesota, with an additional office in La Jolla, California, StemoniX offers a platform that focuses on the 3-D printing of stem-cell derived human tissues. This innovative approach allows for the creation of custom drug discovery models and facilitates the development of living cells in larger formats, addressing various medical conditions such as heart disease, dementia, breast cancer, autism, and ALS. The company's platform also operationalizes human induced pluripotent stem cell (iPSC) disease models for high-throughput screening, improving the research process for neurotoxicity and other drug screening efforts.

Caraway Therapeutics, Inc. is a biotechnology company focused on developing innovative treatments for neurodegenerative diseases through the modulation of mitophagy and autophagy. By targeting genetically defined pathways, the company aims to create small molecules that restore cellular balance and address the underlying mechanisms of diseases such as Parkinson's disease and amyotrophic lateral sclerosis. Founded in 2018 and based in Cambridge, Massachusetts, Caraway Therapeutics seeks to improve the lives of patients affected by these debilitating conditions by leveraging its expertise in cellular degradation processes. The company was previously known as Rheostat Therapeutics, Inc. before rebranding in October 2019.

Ambient Clinical Analytics, Inc. develops healthcare data assimilation and decision support tools aimed at enhancing patient care in intensive care units, operating rooms, and emergency departments. The company's flagship product, AWARE, integrates with various electronic health record systems and bedside monitors to deliver crucial patient information on a single-screen dashboard, facilitating real-time clinical decision-making. Additionally, Ambient offers the Mayo Clinic YES Board, which enhances patient flow by providing real-time situational awareness. The company also specializes in syndromic surveillance solutions, including Sepsis DART, which aids in the detection and confirmation of sepsis, and the Ventilator-Induced Lung Injury Sniffer, designed for ventilator monitoring. Furthermore, Ambient provides the Synthesis Platform, which serves as an integration tool for AWARE and the Mayo Clinic solutions. Founded in 2013 and headquartered in Rochester, Minnesota, Ambient Clinical Analytics focuses on reducing healthcare costs and improving patient outcomes through its innovative tools and technology.

Geneticure Inc. is a pharmacogenetic testing company based in Eden Prairie, Minnesota, founded in 2012. The company specializes in developing tests that enable personalized medicine, particularly for patients with hypertension. Geneticure has created a patented cheek-swab test that predicts individual responses to high blood pressure medications and therapies. The testing process involves DNA extraction and genotyping, and the results are directly provided to healthcare providers alongside a summary of the genetic findings and a decision tree for treatment optimization. These tools are designed to assist clinicians in determining the most effective treatment methods for managing high blood pressure, ultimately allowing patients to utilize painless and affordable at-home testing to reach their blood pressure goals. Geneticure is backed by the Mayo Clinic, emphasizing its commitment to clinical evidence and personalized patient care.

Unity Biotechnology is a biotechnology company dedicated to the research and development of therapeutics aimed at extending human health span by addressing diseases associated with aging. The company specializes in clearing senescent cells through the creation of senolytic medicines, which target vulnerabilities specific to these cells while preserving normal ones. Its lead drug candidates include UBX0101, currently undergoing Phase II trials for musculoskeletal disorders and Phase Ib trials for moderate-to-severe knee osteoarthritis, and UBX1325, which is in Phase I trials for diabetic macular edema. Additionally, Unity is exploring treatments for various age-related conditions, including ophthalmologic, pulmonary, kidney, and liver diseases. Founded in 2009 and based in South San Francisco, California, Unity Biotechnology was formerly known as Forge, Inc. and rebranded in 2015.

Helix is a prominent population genomics company that focuses on the convergence of clinical care, research, and genomics. Its comprehensive platform assists health systems, life sciences companies, and payers in advancing genomic research and integrating genomic data into clinical practice. Helix operates one of the world's largest CLIA/CAP-certified next-generation sequencing labs and utilizes its proprietary Exome+ assay to support various aspects of population genomics, including participant recruitment, disease screening, result reporting, and both basic and translational research.

Helixis, Inc. is a company that develops low-cost molecular diagnostic products.

Progentec Diagnostics, Inc. is a company focused on developing innovative diagnostic tests for managing systemic lupus erythematosus (SLE). Established in 2015 and headquartered in Oklahoma City, Oklahoma, the company has created the aiSLE DX platform, which offers tools like a flare prediction score to measure disease activity in SLE patients and an early diagnostic test for lupus. Progentec integrates advanced technology and collaborates with research institutions globally, aiming to address significant unmet needs in diagnostic interventions. The company's mission centers on improving disease management and reducing disease incidence through enhanced screening and early detection.

Unity Biotechnology is a biotechnology company dedicated to the research and development of therapeutics aimed at extending human health span by addressing diseases associated with aging. The company specializes in clearing senescent cells through the creation of senolytic medicines, which target vulnerabilities specific to these cells while preserving normal ones. Its lead drug candidates include UBX0101, currently undergoing Phase II trials for musculoskeletal disorders and Phase Ib trials for moderate-to-severe knee osteoarthritis, and UBX1325, which is in Phase I trials for diabetic macular edema. Additionally, Unity is exploring treatments for various age-related conditions, including ophthalmologic, pulmonary, kidney, and liver diseases. Founded in 2009 and based in South San Francisco, California, Unity Biotechnology was formerly known as Forge, Inc. and rebranded in 2015.

DayTwo Ltd. is a precision nutrition company headquartered in Tel Aviv-Yafo, Israel, that focuses on leveraging gut microbiome insights to improve health outcomes and prevent diseases such as diabetes, prediabetes, obesity, and non-alcoholic fatty liver disease (NAFLD). Founded in 2015, DayTwo employs microbiome sequencing to create personalized dietary recommendations, known as Food Prescriptions™, tailored to individual responses to food. This approach helps manage blood sugar levels, enhance energy, control hunger, and promote weight loss. DayTwo delivers its services through a digital platform and mobile application, enabling users to track their progress and communicate with certified diabetes care specialists and registered dietitians. By emphasizing personalized nutrition based on scientific research, DayTwo aims to empower patients to lead healthier lives through informed dietary choices.

Unity Biotechnology is a biotechnology company dedicated to the research and development of therapeutics aimed at extending human health span by addressing diseases associated with aging. The company specializes in clearing senescent cells through the creation of senolytic medicines, which target vulnerabilities specific to these cells while preserving normal ones. Its lead drug candidates include UBX0101, currently undergoing Phase II trials for musculoskeletal disorders and Phase Ib trials for moderate-to-severe knee osteoarthritis, and UBX1325, which is in Phase I trials for diabetic macular edema. Additionally, Unity is exploring treatments for various age-related conditions, including ophthalmologic, pulmonary, kidney, and liver diseases. Founded in 2009 and based in South San Francisco, California, Unity Biotechnology was formerly known as Forge, Inc. and rebranded in 2015.

Chrono Therapeutics Inc. is a pharmaceutical company based in Hayward, California, specializing in digital transdermal drug delivery systems. Founded in 2003, the company has developed SmartStop, a digital nicotine replacement therapy that incorporates a wearable device. This innovative solution allows for programmable delivery of nicotine, adjusting timing and dosage to effectively manage withdrawal symptoms and peak addiction triggers. By combining this transdermal therapy with real-time behavioral support, Chrono Therapeutics aims to enhance smoking cessation efforts and improve clinical outcomes for users. The leadership team brings extensive experience in product development, research and development, and a deep understanding of the smoking cessation market, positioning the company to play a significant role in addressing the smoking epidemic.

Torax Medical, Inc. is a clinical-stage medical device company based in Shoreview, Minnesota, founded in 2002. The company specializes in developing and marketing innovative products aimed at restoring the barrier function of sphincters to treat various digestive diseases. Its primary offerings include LINX, a reflux management system designed for patients with gastroesophageal reflux disease (GERD), and FENIX, a continence restoration system for fecal incontinence. Utilizing specialized magnets, these devices facilitate minimally invasive procedures to address these conditions. Torax Medical operates in both the European and U.S. markets and is a subsidiary of Ethicon, Inc.

Epirium Bio, Inc. is a San Diego-based biopharmaceutical company focused on developing therapeutic compounds for cardiovascular diseases, metabolic syndrome, and various conditions related to mitochondrial dysfunction. Founded in 2008 and previously known as Cardero Therapeutics, Epirium Bio utilizes innovative insights into mitochondrial biology and tissue regeneration to create small molecule therapies. The company's research is aimed at enhancing muscle strength and supporting the treatment of neuromuscular and neurodegenerative disorders, including conditions such as muscular dystrophy. Through its novel approaches, Epirium Bio seeks to provide clinically significant solutions for patients suffering from these challenging diseases.

Helix is a prominent population genomics company that focuses on the convergence of clinical care, research, and genomics. Its comprehensive platform assists health systems, life sciences companies, and payers in advancing genomic research and integrating genomic data into clinical practice. Helix operates one of the world's largest CLIA/CAP-certified next-generation sequencing labs and utilizes its proprietary Exome+ assay to support various aspects of population genomics, including participant recruitment, disease screening, result reporting, and both basic and translational research.

Lifecode, Inc. is a molecular diagnostics company specializing in next-generation sequencing (NGS) technology. Based in Foster City, California, Lifecode develops a range of NGS-based cancer assays, including a pan cancer somatic panel designed for use in metastatic, rare, and refractory cancers, as well as in patients seeking clinical trials. The company aims to assist physicians in making informed treatment decisions by providing clinical information derived from extensive genomic and therapeutic data. Lifecode combines expertise in data science, software engineering, and molecular biology to effectively analyze and interpret complex genetic information. Its flagship product, the Lifecode Pan Cancer Somatic Panel, is currently offered to a select group of physicians in the United States. Lifecode was formerly known as Silicon Valley Biosystems and became a subsidiary of MedGenome Labs Private Ltd. in 2016.

Unity Biotechnology is a biotechnology company dedicated to the research and development of therapeutics aimed at extending human health span by addressing diseases associated with aging. The company specializes in clearing senescent cells through the creation of senolytic medicines, which target vulnerabilities specific to these cells while preserving normal ones. Its lead drug candidates include UBX0101, currently undergoing Phase II trials for musculoskeletal disorders and Phase Ib trials for moderate-to-severe knee osteoarthritis, and UBX1325, which is in Phase I trials for diabetic macular edema. Additionally, Unity is exploring treatments for various age-related conditions, including ophthalmologic, pulmonary, kidney, and liver diseases. Founded in 2009 and based in South San Francisco, California, Unity Biotechnology was formerly known as Forge, Inc. and rebranded in 2015.

AssureRX Health is a personalized medicine company based in Mason, Ohio, specializing in pharmacogenomics. The company aims to assist healthcare providers in identifying the most suitable medications for individual patients suffering from neuropsychiatric and chronic pain conditions. By offering treatment decision support, AssureRX Health enables clinicians to collect and analyze genetic information, ultimately guiding them in prescribing the right medications tailored to each patient's unique genetic profile. This approach enhances treatment efficacy and patient outcomes in behavioral health and other medical contexts.

Ambra Health is a medical data and image management company that provides a cloud-based platform for healthcare providers. The platform is designed to enhance imaging innovation by offering secure and easy access to medical images, facilitating internal adoption, and strengthening collaboration among healthcare organizations. With its intuitive and flexible design, Ambra's solutions enable health systems, radiology practices, and clinical research organizations to improve workflows related to imaging and patient care. The company's technology aims to make medical images and data accessible from anywhere, significantly enhancing operational efficiency and business outcomes within the healthcare sector.

Chrono Therapeutics Inc. is a pharmaceutical company based in Hayward, California, specializing in digital transdermal drug delivery systems. Founded in 2003, the company has developed SmartStop, a digital nicotine replacement therapy that incorporates a wearable device. This innovative solution allows for programmable delivery of nicotine, adjusting timing and dosage to effectively manage withdrawal symptoms and peak addiction triggers. By combining this transdermal therapy with real-time behavioral support, Chrono Therapeutics aims to enhance smoking cessation efforts and improve clinical outcomes for users. The leadership team brings extensive experience in product development, research and development, and a deep understanding of the smoking cessation market, positioning the company to play a significant role in addressing the smoking epidemic.

Pendulum Therapeutics Inc. is a microbiome-focused company based in San Francisco that specializes in developing medical probiotics and prebiotics aimed at managing chronic illnesses, particularly type 2 diabetes. The company's flagship product, Pendulum Glucose Control, was introduced in 2020 and has demonstrated effectiveness in lowering blood sugar spikes and reducing A1C levels, as evidenced by published clinical trials. Pendulum utilizes evidence-based microbiome science and DNA sequencing to create targeted interventions, allowing clinicians to identify specific microbiome markers for disease treatment. Founded in 2013, Pendulum holds 13 patents and has 42 pending, with significant backing from prominent investors. The company sells its products online, focusing on improving healthcare through innovative microbiome therapies.

Ambient Clinical Analytics, Inc. develops healthcare data assimilation and decision support tools aimed at enhancing patient care in intensive care units, operating rooms, and emergency departments. The company's flagship product, AWARE, integrates with various electronic health record systems and bedside monitors to deliver crucial patient information on a single-screen dashboard, facilitating real-time clinical decision-making. Additionally, Ambient offers the Mayo Clinic YES Board, which enhances patient flow by providing real-time situational awareness. The company also specializes in syndromic surveillance solutions, including Sepsis DART, which aids in the detection and confirmation of sepsis, and the Ventilator-Induced Lung Injury Sniffer, designed for ventilator monitoring. Furthermore, Ambient provides the Synthesis Platform, which serves as an integration tool for AWARE and the Mayo Clinic solutions. Founded in 2013 and headquartered in Rochester, Minnesota, Ambient Clinical Analytics focuses on reducing healthcare costs and improving patient outcomes through its innovative tools and technology.

Sanguine is focused on enhancing translational biomedical research by facilitating patient participation. The company offers tools and concierge services that enable patients to engage in medical research from the comfort of their homes, promoting transparency and communication throughout the process. By prioritizing respectful patient support and appropriate compensation, Sanguine aims to improve the overall patient experience and ensure that research biospecimens are more impactful. Through these efforts, Sanguine seeks to bridge the gap between patients and researchers, empowering individuals to contribute directly to the development of personalized medicines and new treatments.

Torax Medical, Inc. is a clinical-stage medical device company based in Shoreview, Minnesota, founded in 2002. The company specializes in developing and marketing innovative products aimed at restoring the barrier function of sphincters to treat various digestive diseases. Its primary offerings include LINX, a reflux management system designed for patients with gastroesophageal reflux disease (GERD), and FENIX, a continence restoration system for fecal incontinence. Utilizing specialized magnets, these devices facilitate minimally invasive procedures to address these conditions. Torax Medical operates in both the European and U.S. markets and is a subsidiary of Ethicon, Inc.

The Kang San Global Medical Technology (Beijing) Co., Ltd. is a hi-tech enterprise of one for the country at all levels of the hospital to provide advanced specialist inspection services, and the establishment of the National Laboratory of Kang Sheng Global Medical Special Inspection Center. Of the center's national service network belongs wholly owned ...

Anexon, Inc. is a pharmaceutical company based in Cambridge, Massachusetts, focused on developing innovative therapeutics for cardiovascular diseases. The company's primary research centers on an alternatively spliced variant of brain natriuretic peptide known as ANX-042. This therapeutic aims to address the needs of patients suffering from chronic heart failure and kidney dysfunction, representing a significant advancement in the treatment of these conditions. Anexon's commitment to biotechnology underscores its dedication to improving patient outcomes in the cardiovascular field.

Torax Medical, Inc. is a clinical-stage medical device company based in Shoreview, Minnesota, founded in 2002. The company specializes in developing and marketing innovative products aimed at restoring the barrier function of sphincters to treat various digestive diseases. Its primary offerings include LINX, a reflux management system designed for patients with gastroesophageal reflux disease (GERD), and FENIX, a continence restoration system for fecal incontinence. Utilizing specialized magnets, these devices facilitate minimally invasive procedures to address these conditions. Torax Medical operates in both the European and U.S. markets and is a subsidiary of Ethicon, Inc.

Kardia Health Systems is a healthcare information technology firm offering the delivery of specialty medicine, starting with cardiology. Using Internet technology and a Software-as-a-Service (SaaS) business model, Kardia makes this technology accessible to practices of varying sizes. Kardia Health Systems, Inc. was incorporated in 2006 and is based in Golden Valley, Minnesota.

Kardia Health Systems is a healthcare information technology firm offering the delivery of specialty medicine, starting with cardiology. Using Internet technology and a Software-as-a-Service (SaaS) business model, Kardia makes this technology accessible to practices of varying sizes. Kardia Health Systems, Inc. was incorporated in 2006 and is based in Golden Valley, Minnesota.

Naviscan, Inc. is the leader in organ-specific molecular imaging. The company designs, manufactures, and distributes a high-resolution PET scanner which provides unprecedented visualization of small body parts. While Naviscan’s PET scanner can image virtually any body part that can fit into the gantry, it is most often utilized as an adjunct to conventional imaging technologies by clinicians who stage and manage breast cancer. Surgeons, radiologists, nuclear physicians, and oncologists in hospitals and breast clinics use our compact, mobile and easy-to-use PET scanner to precisely characterize breast cancer, enhance surgical planning, monitor patient response to therapy, and evaluate suspected recurrence.

Naviscan, Inc. is the leader in organ-specific molecular imaging. The company designs, manufactures, and distributes a high-resolution PET scanner which provides unprecedented visualization of small body parts. While Naviscan’s PET scanner can image virtually any body part that can fit into the gantry, it is most often utilized as an adjunct to conventional imaging technologies by clinicians who stage and manage breast cancer. Surgeons, radiologists, nuclear physicians, and oncologists in hospitals and breast clinics use our compact, mobile and easy-to-use PET scanner to precisely characterize breast cancer, enhance surgical planning, monitor patient response to therapy, and evaluate suspected recurrence.

Torax Medical, Inc. is a clinical-stage medical device company based in Shoreview, Minnesota, founded in 2002. The company specializes in developing and marketing innovative products aimed at restoring the barrier function of sphincters to treat various digestive diseases. Its primary offerings include LINX, a reflux management system designed for patients with gastroesophageal reflux disease (GERD), and FENIX, a continence restoration system for fecal incontinence. Utilizing specialized magnets, these devices facilitate minimally invasive procedures to address these conditions. Torax Medical operates in both the European and U.S. markets and is a subsidiary of Ethicon, Inc.